Shares of Fusion Pharmaceuticals Inc. fell 4.3% in premarket trading on Thursday after the company announced several delays to its oncology program. Fusion said it wouldn’t be able to share Phase 1 clinical trial data for its experimental tumor treatment, FPI-1434, until the first half of next year. Fusion had previously said that data would be made available in the second half of 2022. It also said it will begin dosing patients in a clinical study for FPI-1966 in the second half of this year, instead of the second quarter of 2022. Fusion’s stock is down 12.2% this year, while the broader S&P 500 has declined 12.7%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.